SARS-Cov-2 B.1.617.2 Delta Variant Emergence, Replication
bioRxiv preprint doi: https://doi.org/10.1101/2021.05.08.443253; this version posted July 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 SARS-CoV-2 B.1.617.2 Delta variant emergence, replication and sensitivity to 2 neutralising antibodies 3 4 Petra Mlcochova1,2*, Steven Kemp1,2,6*, Mahesh Shanker Dhar3*, Guido Papa4, Bo Meng1,2, 5 Swapnil Mishra5, Charlie Whittaker5, Thomas Mellan5, Isabella Ferreira1,2, Rawlings Datir1,2, 6 Dami A. Collier,2,6, Anna Albecka4, Sujeet Singh3, Rajesh Pandey7, Jonathan Brown8, Jie 7 Zhou8, Niluka Goonawardne8, Robin Marwal3, Meena Datta3, Shantanu Sengupta7, 8 Kalaiarasan Ponnusamy3, Venkatraman Srinivasan Radhakrishnan3, Adam Abdullahi1,2, Oscar 9 Charles6, Partha Chattopadhyay7, Priti Devi7, Daniela Caputo9, Tom Peacock8, Dr Chand 10 Wattal10, Neeraj Goel10, Ambrish Satwik10, Raju Vaishya11, Meenakshi Agarwal12, The Indian 11 SARS-CoV-2 Genomics Consortium (INSACOG), The CITIID-NIHR BioResource COVID- 12 19 Collaboration, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Antranik 13 Mavousian13, Joo Hyeon Lee13,14, Jessica Bassi15 , Chiara Silacci-Fegni15, Christian Saliba15, 14 Dora Pinto15 , Takashi Irie16, Isao Yoshida17, William L. Hamilton2, Kei Sato18,19, Leo James4, 15 Davide Corti15, Luca Piccoli15, Samir Bhatt4,20,, Seth Flaxman21, Wendy S. Barclay8, Partha 16 Rakshit3*, Anurag Agrawal7*, Ravindra K. Gupta1,2, 22* 17 18 1 Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, 19 UK. 20 2 Department of Medicine, University of Cambridge, Cambridge, UK.
[Show full text]